Nicola Baker of Rushtons Insolvency Limited was appointed as Administrator of the Company on 2 May 2025.
The Company has ceased to trade and the Administrator can be contacted via email on oxford@rushtonsifs.co.uk.
Octavian is at the frontier of precision pain management, developing innovative, non-addictive, small-molecule medicines that target the endocannabinoid system (ECS) to address the global challenge of chronic pain, which affects over 1.5 billion 1 people and drives dangerous dependence on opioids.
Company Details
- Employees
- 5
- Founded
- -
- Address
- Prama House, 267 Banbury Road, Oxford Ox2 7ht, Oxford,england Ox2 7ht,united Kingdom
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- oxcantech.com
- Keywords
- London.
- HQ
- Oxford, England
Octavian Therapeutics Questions
Octavian Therapeutics's website is oxcantech.com
Octavian Therapeutics's LinkedIn profile is https://uk.linkedin.com/company/octavian-therapeutics
Octavian Therapeutics has
5 employees.
View email and phone details for 5
employees at Octavian Therapeutics.
Octavian Therapeutics's industry is
Pharmaceutical Manufacturing
Octavian Therapeutics's top competitors are
Fieldfisher,
Kanabo,
Celadon Pharmaceuticals Plc,
Ananda Pharma Plc,
Cannaray Brands,
Zapgo,
Gw Pharmaceuticals Plc,
Province Brands Of Canada,
Robin Ai,
Futura Medical.
Octavian Therapeutics's categories are Pharmaceutical Manufacturing
Octavian Therapeutics's founding year is 2017
